Clinical trials: Coronavirus 2019
Coronavirus Infection, Acute Respiratory Failure
Early Prone Position on Coronavirus Disease 2019 Pneumonia
the purpose of this study to evaluate the effect of early awake PP (prone position)application on oxygenation and intubation requirement in patients with acute respiratory failure due to coronavirus disease 2019 pneumonia.
- Trial name
- Prone Position (NCT04427969)
- Testing
- prone position
- Where
- Turkey (Türkiye)
- Volunteers
- 33 people
- Sponsor
- Sisli Hamidiye Etfal Training and Research Hospital
Coronavirus Disease 2019, Coronavirus Disease 2019 (COVID-19)
A Study of How Ibuzatrelvir is Taken up Into the Blood of Healthy Adults After Taking Different Tablets of Ibuzatrelvir
Healthy adults will be enrolled into this open-label, Phase 1 research study. Participants will spend about 9 nights and 10 days in the clinical research unit (CRU) and the total time in the study will be about 11 weeks.
- Conditions
- Coronavirus Disease 2019, Coronavirus Disease 2019 (COVID-19), COVID-19 (Coronavirus Disease 2019), Upper Respiratory Tract Infections
- Trial name
- NCT07552779
- Testing
- Ibuzatrelvir co-process API film coated tablet, Ibuzatrelvir filmcoated tablet
- Where
- Belgium
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- Pfizer
COVID-19
A Study to Evaluate Safety and Efficacy of Convalescent Methylene Blue Treated (MBT) Plasma From Donors Recovered From Coronavirus Disease 2019 (COVID-19)
The purpose of the study is to determine if Convalescent anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Methylene Blue Treated (MBT) plasma plus Standard Medical Treatment (SMT) can reduce all-cause mortality…
- Trial name
- NCT04547127
- Testing
- Convalescent anti-SARS-CoV-2 MBT Plasma, Standard Medical Treatment
- Where
- 12 sites in Spain
- Volunteers
- 200 people
- Sponsor
- Instituto Grifols, S.A.
Pharmacokinetics, Safety Issues
Pharmacokinetics, Safety and Efficacy Study of GP30341 (GEROPHARM, Russia)
Pharmacokinetics, safety and efficacy study of GP30341, 200 mg capsules (GEROPHARM LLC, Russia) in healthy volunteers and patients with novel coronavirus infection 2019 (COVID-19) with a high risk of adverse outcome
- Conditions
- Pharmacokinetics, Safety Issues, Efficacy
- Trial name
- NCT05648799
- Testing
- GP30341 capsules 200 mg, Standard therapy
- Where
- 5 sites in Russia
- Volunteers
- 246 people, healthy volunteers welcome
- Sponsor
- Geropharm
Covid19
SARS-CoV-2 CTLS for Mild to Moderate COVID-19 Disease
The 2019 Severe Acute Respiratory Syndrome (SARS) is a global pandemic secondary to a novel coronavirus - SARS-CoV-2. The reported case-fatality ratio for SARS-CoV-2 in the United States is 1.8% with a current death toll of…
- Trial name
- NCT04896606
- Testing
- Standard of Care, SARS-CoV2-CTLS
- Where
- 4 sites in United States
- Volunteers
- 50 people
- Sponsor
- New York Medical College
Antithrombin III Deficiency, Covid19
Antithrombin III in Infectious Disease Caused by COVID-19
The purpose of this research study is to see if participants who have SARS-CoV-2 and low levels of AT3 in the blood will benefit by being given AT3.
- Trial name
- NCT04899232
- Testing
- Antithrombin III
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Enrique Ginzburg
Acute Coronary Syndrome, Chronic Heart Failure
Influenza Vaccination During Coronavirus Disease 2019 Outbreak After Acute Coronary Syndrome and Chronic Heart Failure
Study Description: Background: Well-known fact that the number of cardiovascular diseases is on the rise during influenza epidemic.
- Trial name
- IV-ACS&CHF (NCT05232292)
- Testing
- Ultrix Quadri
- Where
- Russia
- Volunteers
- 200 people
- Sponsor
- Samara Regional Cardiology Dispensary
COVID - 19
Safety and Immunogenicity of a Chimeric Recombinant Covid19 Vaccine SpiN-Tec MCTI UFMG
SpiN-Tec MCTI UFMG will be used as a vaccine booster against COVID-19 and will be evaluated using the active comparator, a vaccine approved by ANVISA (Brazilian Health Regulatory Agency).
- Trial name
- SpiN-Tec-001 (NCT07134725)
- Testing
- SpiN-Tec MCTI UFMG, Active Comparator: Covishield® vaccine, Active Comparator: Comirnaty® vaccine
- Where
- Brazil
- Volunteers
- 432 people, healthy volunteers welcome
- Sponsor
- Federal University of Minas Gerais
Acute Respiratory Distress Syndrome, COVID-19
A Study of Brexanolone for Acute Respiratory Distress Syndrome (ARDS) Due to Coronavirus Disease 2019 (COVID-19)
The purpose of this study was to evaluate the efficacy and safety of brexanolone in participants on ventilator support for acute respiratory distress syndrome (ARDS) due to COVID-19.
- Trial name
- NCT04537806
- Testing
- Brexanolone
- Where
- 9 sites in United States
- Volunteers
- 29 people
- Sponsor
- Sage Therapeutics
Pneumonia, Ventilator-Associated, Coronavirus Infection
Convalescent Antibodies Infusion in Critically Ill COVID 19 Patients
The 2019 outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 or COVID 19), which originated in Wuhan, China, has become a major concern all over the world.
- Trial name
- NCT04346589
- Testing
- Anti-coronavirus antibodies (immunoglobulins)obtained with DFPP from convalescent patients
- Where
- 5 sites in Italy
- Volunteers
- 9 people
- Sponsor
- A.O. Ospedale Papa Giovanni XXIII
Neoplasms, Coronavirus
ASCO Survey on COVID-19 in Oncology (ASCO) Registry
The American Society of Clinical Oncology (ASCO) Survey on Coronavirus 2019 (COVID-19) in Oncology Registry (ASCO Registry) aims to help the cancer community learn more about the patterns of symptoms and severity of COVID-19…
- Trial name
- NCT04659135
- Where
- 77 sites in United States
- Volunteers
- 7,000 people
- Sponsor
- American Society of Clinical Oncology
Coronavirus Disease 2019 (COVID-19)
Non-Interventional Enhanced Active Surveillance Study of Adults Vaccinated With AZD1222
This is a Phase IV real-world, observational, non-interventional, prospective cohort study of adults vaccinated with AZD1222. The purpose of this study is to assess the safety and tolerability of AZD1222 in adults vaccinated in…
- Trial name
- COVID-19 (NCT04877743)
- Testing
- None (Observational study)
- Where
- Germany
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
COVID-19 Disease
Study of LAU-7b for the Treatment of Coronavirus Disease 2019 (COVID-19) Disease in Adults
A randomized, double-blind, placebo-controlled Phase 2/3 Study of LAU-7b against confirmed COVID-19 Disease in hospitalized patients at a higher risk of complications.
- Trial name
- RESOLUTION (NCT04417257)
- Testing
- LAU-7b
- Where
- 29 sites in United States, Canada
- Volunteers
- 351 people
- Sponsor
- Laurent Pharmaceuticals Inc.
Healthy Participants
A Study to Learn About the Study Medicine PF-07321332 and Ritonavir in Adult Healthy Chinese Participants.
The purpose of this Phase 1 clinical trial is to help us understand how the drug is changed and eliminated from your body after you take it, the safety, and the the extent to which dise effects can be tolerated of PF-07321332…
- Trial name
- NCT05339334
- Testing
- PF-07321332/ritonavir
- Where
- China
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Pfizer
Coronavirus Disease 2019 (COVID-19) Pneumonia
Mesenchymal Stem Cells Therapy in Patients With COVID-19 Pneumonia
Due to the cytokine storm that develops as a result of Coronavirus Disease 2019 (COVID-19) infection, some patients hospitalization to intensive care cause of pneumonia, Acute Respiratory Distress Syndrome (ARDS) and multiple…
- Trial name
- NCT04713878
- Testing
- Mesenchymal stem cells
- Where
- Turkey (Türkiye)
- Volunteers
- 21 people
- Sponsor
- Kanuni Sultan Suleyman Training and Research Hospital
Covid19, Hydrogen-oxygen Gas
Hydrogen-oxygen Gas Mixture Inhalation in Patients With Convalescent Coronavirus Disease 2019 (COVID-19)
This study is a multicenter, randomized, open, parallel-controlled study. Qualified subjects will randomly be assigned to the experimental arm or the control arm according to the ratio of 1:1, with age (> 60 years or ≤ 60 years)…
- Conditions
- Covid19, Hydrogen-oxygen Gas, AMS-H-03
- Trial name
- NCT04594460
- Testing
- Hydrogen-Oxygen Generator with Nebulizer, AMS-H-03, OLO-1 Medical Molecular Sieve Oxygen Generator
- Where
- 2 sites in China
- Volunteers
- 198 people
- Sponsor
- Guangzhou Institute of Respiratory Disease
Covid19 and Mortality
Factors Affecting Mortality in Critical Patients Admitted to Intensive Care Unit Due to Coronavirus Disease 2019
Gazi Yasargil Training and Research Hospital, located in Diyarbakır province in southeastern Turkey, was designed as a pandemic hospital from the beginning of the coronavirus disease-2019 (COVID-19) outbreak.
- Trial name
- NCT04659876
- Testing
- clinical features and laboratory values
- Where
- Turkey (Türkiye)
- Volunteers
- 445 people
- Sponsor
- Saglik Bilimleri Universitesi Gazi Yasargil Training and Research Hospital
Covid19, Sars-CoV-2 Infection
Post Acute Sequelae of COVID-19
COVID-19, a novel coronavirus, has caused widespread mortality and morbidity since it emerged in 2019. There is ongoing research and growing literature describing severe acute respiratory syndrome (SARS-COV-2).
- Conditions
- Covid19, Sars-CoV-2 Infection, Dyspnea Caused by 2019-nCoV, COVID-19 Acute Respiratory Distress Syndrome
- Trial name
- PASC (NCT04964115)
- Testing
- Cohort study
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- Vanderbilt University Medical Center
Coronavirus, N95
Medical Masks vs N95 Respirators for COVID-19
A randomized controlled trial in which health care workers will be randomized to either medical masks or N95 respirators when providing care to patients with COVID-19.
- Conditions
- Coronavirus, N95, Medical Mask
- Trial name
- NCT04296643
- Testing
- Medical Mask, N95 respirator
- Where
- 15 sites in Canada, Egypt and 2 more
- Volunteers
- 1,009 people
- Sponsor
- McMaster University
Covid19 Virus Infection
Medical Herbs Inhibit Inflammation Directing T Cells to Kill the COVID-19 Virus (COVID)
The human immune system is designed to protect individuals from external sources of infection and internal cell mutation. It works effectively and efficiently until inflammation disturbs its functioning.
- Trial name
- COVID (NCT04790240)
- Testing
- Inflammation (I), Inflammation (II), Inflammation (III)
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- All Natural Medicine Clinic, LLC